GILD

GILD Breakout Activated — XLV Gave the Clue, Price Gave the Trad NASDAQ:GILD has activated the breakout setup at 141.84 after building a constructive structure beneath resistance. The setup developed while AMEX:XLV was pushing into all-time highs, putting Health Care on our radar for individual stock opportunities. The sector gave the clue. The stock still had to confirm. Price has now done its part. Breakout Trigger: 141.84 Status: Elite Position Activated The focus from here shifts from entry to risk management. E ducational purposes only. Not financ

by SniperAlphaResearch

GILD — A 10-Year Base Breaks: The 2015 Ceiling Is Now the Floor NASDAQ:GILD Gilead spent almost a decade going nowhere. The June 2015 peak near 123 capped every rally attempt for nine straight years, while price ground sideways between the mid-50s and the low-90s. On a monthly chart that is not a range — that is a base, and one of the longest and cleanest ones on the large-cap biotech board. That base is now resolved. Price has cleared the 2015 high, backfilled into it, and is holding above it. The old ceiling has flipped into the floor, which is exactly t

GILD Long — GILD reclaims support and holds above VWAP as fresh…GILD is a long pullback with price reclaiming intraday support and holding above VWAP while still sitting close enough to the base to avoid a chase. The fresh oncology regulatory recommendation and recent HIV pipeline progress give the bounce a real catalyst, though the mixed analyst tape keeps this from being a full-confidence breakout chase. 📍 Entry: 131.01 🛑 Stop: 128.11 🎯 Target: 140.61 ⚖️ R:R: 3.31

GILD Long — Rejection off resistance plus a fresh EMA catalyst l Bearish 4h structure into the 140.61 resistance with a clean rejection trigger favors the long side; the recent EMA recommendation adds a concrete regulatory catalyst that aligns with and strengthens the pullback long thesis. 📍 Entry: 131.01 🛑 Stop: 128.11 🎯 Target: 140.61 ⚖️ R:R: 3.31

$GILD double bottom set up GILD Fundamental Analysis Gilead Sciences has demonstrated resilient core performance driven by its HIV and antiviral franchises, with Q1 2026 revenue of approximately $6.96 billion, up about 4 % year-over-year, and net income expanding over 50 % versus the prior year on EPS of $1.61 (diluted) – outperforming consensus expectations. The company also raised full-year 2026 product sales guidance to about $30–30.4 billion, supported by strong demand for its HIV portfolio and growth in key thera

by SmiertSpionam

Gilead Sciences — Durable HIV Cash Engine, Expanding Oncology Market Overview Gilead NASDAQ:GILD is a leading biopharma with a durable HIV franchise and a scaling oncology portfolio. Biktarvy (U.S. exclusivity to 2036) underpins predictable cash flows to fund growth in oncology and inflammation. Key Catalysts HIV Leadership: Biktarvy’s longevity funds pipeline; lenacapavir (long-acting prevention) adds medium-term upside. Oncology Momentum: Trodelvy growth across breast/bladder; pipeline enhanced by assets like Repare’s Polθ inhibitor. Visibility: Mult

by Richtv_official

$GILD Tradespoon – Neutral Entry $127.51 Tradespoon model shows a neutral signal for $ NASDAQ:GILD . Predicted range: $125.13–$128.02. Trend: –0.37%. NASDAQ:GILD

by yellowtunnel

GILD 5M Short CounterTrend Daytrade (Buy Put to Open)5M CounterTrend Trade - long impulse + exhaustion volume 1H CounterTrend "- long impulse + volumed T1 + resistance zone + volumed reaction bar" 1D CounterTrend "- long impulse - unvolumed T1 + resistance level + volumed manipulation bar " 1M CounterTrend "- long impulse + volumed T1 level + resistance zone" 1Y CounterTrend "- long impulse - unvolumed T1 + resistance zone"

by MishaSuvorov

Gilead Sciences (GILD) Soars 4.93% on Strong Q4 Earnings Reports Gilead Sciences (NASDAQ: NASDAQ:GILD ) is making waves in the biotech sector after delivering a stellar fourth-quarter earnings report that not only crushed Wall Street expectations but also set the stage for a promising 2025. The stock surged 4.50% in premarket trading on Wednesday, signaling strong investor confidence in the company’s growth trajectory. Quarter and Optimistic Guidance Gilead’s Q4 earnings report was nothing short of impressive. The company posted adjusted earnings of $1.90 p

GILD Gilead Sciences Options Ahead of Earnings Analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 89usd strike price Calls with an expiration date of 2024-11-15, for a premium of approximately $2.91. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.

Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from there. However, the outlook remains uncertain. We hope that the stock does not fall below this range bottom, as it would prompt us to consider cutti

by freeguy_by_wmc

Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍. If you take a closer look, you’ll see tha

by freeguy_by_wmc

GILD will be selected for the new Tamiflu vaccine for Pandemic2 It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!). After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines.

by EmptyEternity

GILD potential Buy setup Reasons for bullish bias: - Safe entry at LH breakout - Price bounce from support - Bullish divergence - Positive Earnings Here are the recommended trading levels: Entry Level(Buy stop): 68.59 Stop Loss Level: 64.05 Take Profit Level 1: 71.98 Take Profit Level 2: 84.79 Take Profit Level 3: Open

by TradeWithParas

GILD potential buy setup Reasons for bullish bias: - Bounce from strong support - Bullish engulfing candle formed at weekly closing Entry Level(CMP): 75.58 Stop Loss Level: 71.20 Take Profit Level 1: 79.96 Take Profit Level 2: 84.34 Take Profit Level 3: Open

by TradeWithParas

GILD Gilead Sciences Options Ahead of Earnings If you haven`t bought GILD before the previous earnings: Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 80usd strike price Calls with an expiration date of 2024-6-21, for a premium of approximately $3.10. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.

Gilead's Trodelvy Faces Setback in Lung Cancer Trial In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival for previously treated patients. Despite a noted three-month survival benefit for a subgroup, the overall outcome fell short of statis

GILD 6-Year Resistance Idea GILD is pushing a 6-year resistance line. It broke through for a few days a year ago before being battered back down. Let's see if it'll make the move stick this time.

GILD - Setting up for multi year run Monthly chart is setting up nicely. if it takes out 88, ATH should be quick. stop loss: 79

by CheelooTrader

GILD Gilead Sciences Options Ahead of Earnings If you haven`t bought GILD on the Remdesivir approval: Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 80usd strike price in the money Calls with an expiration date of 2024-1-19, for a premium of approximately $4.25. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.

GILD Short This trade has multiple patterns on M15, and it is with the trend. All timeframes are overbought and have divergence, this trade should be able to fall to the bottom and maybe even more as it is hitting the H4 moving average and has the strength to fall especially with the news regarding Isreal as of now.

by JavonDias_Trading

Let's short Gilead! GILD XABCD, ABC patterns at play. Confirmation via eMA, candlestick pattern. Here we go. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to.

by Rykin_Capital

$GILD: Nice setup for a month...Gilead offers a very nice setup here, upside as per the chart. You can expect it to do well during January if it holds over $85.43 for the most part, might consolidate again after February the 1st. Best of luck if taking this one. Cheers, Ivan Labrie.

GILD SELL+++++ GILD has been stubborn AF on correcting, it will eventually and likely after my puts expire Jan 20 lol.

by ShortSeller76